Ovoca Bio is a European-based biopharmaceutical company with a focus on women s health. The Company is currently developing a novel treatment for women with hypoactive sexual desire disorder (HSDD). The Company s lead product, BP-101, a novel synthetic peptide administered through a nasal spray, is clinically validated, with Phase II and Phase III studies conducted in Russia demonstrating statistically significant improvement in a number of key efficacy outcomes, including an increase in female sexual desire and reduction of symptoms of distress associated with HSDD. Ovoca Bio is seeking to develop the drug for major global markets - in particular the United States and Europe, as well as obtain marketing approval in the Russian Federation.